Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report

BACKGROUND: Bevacizumab is an antiangiogenic agent, and that synergizes with chemotherapeutic drugs. When used in combination therapies, Bevacizumab is associated with adverse events such as hemorrhage, gastrointestinal perforation, delayed wound healing, and pneumothorax. However, the molecular mec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozaki, Yuri, Yoshimura, Akiyo, Sawaki, Masataka, Hattori, Masaya, Gondo, Naomi, Kotani, Haruru, Adachi, Yayoi, Kataoka, Ayumi, Sugino, Kayoko, Horisawa, Nanae, Endo, Yuka, Nozawa, Kazuki, Sakamoto, Shoko, Iwata, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407928/
https://www.ncbi.nlm.nih.gov/pubmed/32821655
http://dx.doi.org/10.5306/wjco.v11.i7.504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407928/
https://www.ncbi.nlm.nih.gov/pubmed/32821655
http://dx.doi.org/10.5306/wjco.v11.i7.504

Ejemplares similares